Mechanisms of Probiotics in Alcoholic Liver Disease
益生菌治疗酒精性肝病的机制
基本信息
- 批准号:10457385
- 负责人:
- 金额:$ 21.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-15 至 2022-12-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAgonistAlcohol-Induced DisordersAlcoholic Liver DiseasesAryl Hydrocarbon ReceptorBacteriaBacterial TranslocationBilophila wadsworthiaCellsChronicDevelopmentDigestive System DisordersDiseaseEndocytosisEnvironmentEpithelialEpithelial CellsExperimental ModelsGingerGoalsGrowthHomeostasisIntestinesLactobacillus casei rhamnosusLeadLiver diseasesMediatingMusNatural regenerationOxidative StressPathogenicityPathway interactionsPlayPreventionPrevention strategyProbioticsProductionReceptor SignalingRoleSignal TransductionTestingTherapeutic EffectTight JunctionsTryptophanUp-Regulationalcohol abuse therapyalcohol exposurearyl hydrocarbon receptor ligandbasedysbiosisexosomegut colonizationgut inflammationgut microbiotaimprovedinterleukin-22intestinal barrierintestinal epitheliumisletmetabolomicsmicrobialmouse modelnanoparticlenovel therapeutic interventionpathogenic bacteriaprebioticspreventprobiotic therapyprotective effecttranscytosis
项目摘要
Probiotics have been used to prevent/treat a variety of digestive diseases including alcoholic liver disease (ALD).
Live probiotics need to colonize the gut to exert their function. Unfortunately, underlying disease states provide
an unfavorable environment for probiotic bacterial gut colonization, which diminishes probiotics’ function. In last
few years, we showed that LGG culture supernatant (LGGs, without live bacteria) was effective in the prevention
of ALD in experimental models of acute and chronic alcohol exposure in mice. However, how LGG supernatant
exerts its therapeutic effects is not fully understood. Exosomes are nanoparticles (NPs) derived from cell
endocytosis which act as transmitters between cells. Recent studies show that bacteria, both Gram-negative
and Gram-positive, produce NPs. The NPs derived from “bad” bacteria have been demonstrated to be
pathogenic. However, “good” bacteria-, probiotics-derived NPs have not been studied. Our preliminary study
showed that administration of LGG-derived exosome-like NPs (LDNPs) effectively reversed ALD in binge-on-
chronic alcohol exposure mouse model, suggesting that probiotic LGGs may exert its function through LDNPs
in ALD. LDNPs administration markedly increased intestinal AhR activity, IL-22, regenerating islet-derived 3
(Reg3) beta and gamma expression, which play a key role in maintaining gut microbiota homeostasis and
preventing bacterial intestinal transcytosis. In addition, LDNPs administration significantly increased intestinal
epithelial cell (IEC) tight junctions and decreased circulating LPS concentration, associated with upregulation of
intestinal Nrf2 signaling, which is known for protecting intestinal barrier junctions against oxidative stress-induced
damage by alcohol. Metabolomic analysis revealed that LDNPs contain high levels of microbial metabolites of
tryptophan, which are AhR ligands, indicating LDNPs may activate intestinal AhR signaling. Furthermore, we
demonstrated that ginger exosome-like nanoparticles (GDNPs) are preferentially taken up by LGG, suggesting
that GDNP may serve as a prebiotic to enhance the effects of LGG. These preliminary studies provide the
groundwork for our central hypothesis that, by activating intestinal AhR-Nrf2 signaling, LDNPs increase intestinal
expression of Il-22, Reg3 and tight junctions, and modulate gut microbiota homeostasis and enhance intestinal
barrier function, leading to the suppression of ALD. We will test our hypothesis in following three specific aims:
(1) Determine the role of bacteria-derived NPs in ALD; (2) Define the mechanisms of the beneficial effect of
LDNPs in ALD; (3) Determine whether ginger-derived exosome-like nanoparticles (GDNPs) treatment enhances
LDNP production and AhR agonist enrichment that lead to improved effects of LDNPs against ALD. Completion
of this study is expected to significantly impact the development of LGG-based probiotic therapeutics in the
treatment of alcohol-associated liver diseases.
益生菌已被用于预防/治疗各种消化系统疾病,包括酒精性肝病(ALD)。
活的益生菌需要在肠道中定植以发挥其功能。不幸的是,潜在的疾病状态提供了
益生菌肠道定植的不利环境,这会降低益生菌的功能。近
几年来,我们发现LGG培养上清液(LGG,不含活菌)在预防中是有效的
在急性和慢性酒精暴露的小鼠实验模型中的ALD。然而,LGG上清液
发挥其治疗作用还不完全清楚。外来体是来源于细胞的纳米颗粒(NP),
内吞作用,其作为细胞之间的传递物。最近的研究表明,细菌,无论是革兰氏阴性,
和革兰氏阳性菌产生NP。来自“坏”细菌的NP已被证明是
致病的然而,“好的”细菌-益生菌-衍生的NP尚未被研究。我们的初步研究
显示LGG衍生的外泌体样NP(LDNP)的施用有效地逆转了酗酒中的ALD。
慢性酒精暴露小鼠模型,表明益生菌LGGs可能通过LDNPs发挥其功能
在ALD。LDNPs给药显著增加肠AhR活性、IL-22、再生胰岛衍生3
(Reg 3)β和γ表达,其在维持肠道微生物群稳态中起关键作用,
防止细菌的肠道转胞吞作用。此外,LDNPs给药显著增加了肠内
上皮细胞(IEC)紧密连接和循环LPS浓度降低,与
肠Nrf 2信号传导,其已知用于保护肠屏障连接免受氧化应激诱导的损伤。
酒精的伤害。代谢组学分析显示LDNP含有高水平的微生物代谢物,
色氨酸,它们是AhR配体,表明LDNP可以激活肠道AhR信号传导。而且我们
证明姜外泌体样纳米颗粒(GDNP)优先被LGG摄取,表明
GDNP可以作为益生元来增强LGG的作用。这些初步研究提供了
为我们的中心假设奠定了基础,即通过激活肠道AhR-Nrf 2信号传导,LDNPs增加了肠道
IL-22、Reg 3和紧密连接的表达,并调节肠道微生物群的稳态和增强肠道
屏障功能,导致ALD的抑制。我们将在以下三个具体目标中检验我们的假设:
(1)确定细菌来源的NPs在ALD中的作用;(2)确定细菌来源的NPs的有益作用的机制。
(3)确定姜衍生的外泌体样纳米颗粒(GDNP)处理是否增强ALD中的LDNP;
LDNP产生和AhR激动剂富集导致LDNP对ALD的改善的效果。完成
这项研究的结果预计将显著影响基于LGG的益生菌治疗剂在美国的发展。
酒精相关性肝病的治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WENKE FENG其他文献
WENKE FENG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WENKE FENG', 18)}}的其他基金
Cannabidiol as a treatment for alcoholic liver disease
大麻二酚治疗酒精性肝病
- 批准号:
10753729 - 财政年份:2023
- 资助金额:
$ 21.73万 - 项目类别:
Intestine FXR activation by LGG-derived nanoparticles in alcohol-associated liver disease
LGG 衍生纳米颗粒在酒精相关性肝病中激活肠道 FXR
- 批准号:
10531712 - 财政年份:2022
- 资助金额:
$ 21.73万 - 项目类别:
Intestine FXR activation by LGG-derived nanoparticles in alcohol-associated liver disease
LGG 衍生纳米颗粒在酒精相关性肝病中激活肠道 FXR
- 批准号:
10794805 - 财政年份:2022
- 资助金额:
$ 21.73万 - 项目类别:
Probiotic-derived nano-particles in alcoholic liver disease
益生菌衍生的纳米颗粒治疗酒精性肝病
- 批准号:
10056416 - 财政年份:2016
- 资助金额:
$ 21.73万 - 项目类别:
Probiotic-derived nano-particles in alcoholic liver disease
益生菌衍生的纳米颗粒治疗酒精性肝病
- 批准号:
10625858 - 财政年份:2016
- 资助金额:
$ 21.73万 - 项目类别:
Mechanisms of Probiotics in Alcoholic Liver Disease
益生菌治疗酒精性肝病的机制
- 批准号:
9325388 - 财政年份:2015
- 资助金额:
$ 21.73万 - 项目类别:
Mechanisms of Probiotics in Alcoholic Liver Disease
益生菌治疗酒精性肝病的机制
- 批准号:
10250531 - 财政年份:2015
- 资助金额:
$ 21.73万 - 项目类别:
Mechanisms of Probiotics in Alcoholic Liver Disease
益生菌治疗酒精性肝病的机制
- 批准号:
9766984 - 财政年份:2015
- 资助金额:
$ 21.73万 - 项目类别:
Mechanisms of Probiotics in Alcoholic Liver Disease
益生菌治疗酒精性肝病的机制
- 批准号:
10794806 - 财政年份:2015
- 资助金额:
$ 21.73万 - 项目类别:
FGF21 and adipose lipolysis in alcoholic fatty liver
FGF21 与酒精性脂肪肝中的脂肪分解
- 批准号:
8702281 - 财政年份:2014
- 资助金额:
$ 21.73万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 21.73万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 21.73万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 21.73万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 21.73万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 21.73万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 21.73万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 21.73万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 21.73万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 21.73万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 21.73万 - 项目类别:
Grant-in-Aid for Scientific Research (C)